Back to Journals » Pathology and Laboratory Medicine International » Volume 7

BRAF G596R mutation in a slow-progressing melanoma

Authors Gao L, Ma D

Received 11 May 2015

Accepted for publication 15 July 2015

Published 17 August 2015 Volume 2015:7 Pages 63—66

DOI https://doi.org/10.2147/PLMI.S88369

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Xuehui Li

Peer reviewer comments 4

Editor who approved publication: Dr Paul Zhang

Ling Gao, Deqin Ma

Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

Abstract: More than 50% of melanomas harbor a single V600E point mutation in the kinase domain of the BRAF gene, resulting in constitutive activation of the MAP kinase pathway. The kinase loop in BRAF begins with Asp-Phe-Gly (DFG; codons 594–596). Mutations in this region are rare, and the effect on tumorigenesis or progression is unknown. We present a slow-progressing metastatic melanoma with a p.G596R (c.1786G>C) mutation in an 84-year-old female. This mutation has only been reported in two cases of melanoma in the current literature, with no clinical information available. Mutations in the DFG motif are considered low-activating through indirect binding and allosteric activation of the CRAF protein. Our patient has carried a clinical diagnosis of melanoma for over 25 years, suggesting that the G596R mutation may be associated with her indolent clinical course. It is unknown whether patients carrying this mutation will benefit from vemurafenib therapy. Our patient declined medical treatment.

Keywords: melanoma, BRAF, V600E, G596R

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Molecular and immunohistochemical profiling of invasive micropapillary carcinoma of the breast

Thomas A, Askeland RW, Guseva NV, Sompallae R, Ma D

Pathology and Laboratory Medicine International 2014, 6:33-40

Published Date: 3 October 2014

Readers of this article also read:

Advances in cancer pain from bone metastasis

Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY

Drug Design, Development and Therapy 2015, 9:4239-4245

Published Date: 18 August 2015

Ulcerative colitis six years after colon cancer: only a coincidence?

Sakellakis M, Makatsoris T, Gkermpesi M, Peroukidis S, Kalofonos H

International Medical Case Reports Journal 2014, 7:85-88

Published Date: 29 April 2014

Update of research on the role of EZH2 in cancer progression

Shen L, Cui J, Liang S, Pang Y, Liu P

OncoTargets and Therapy 2013, 6:321-324

Published Date: 4 April 2013

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012